Rúben Faria

Dr. Rúben Faria

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
ANA.R. Neves
A.R. Neves
Ângela SousaÂngela Sousa
Ângela Sousa
RFRúben Faria
Rúben Faria
TAT. Albuquerque
T. Albuquerque
JQJ.A. Queiroz
J.A. Queiroz
Diana Barata CostaDiana Barata Costa
Diana Barata Costa

1 November 2019 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Ângela SousaÂngela Sousa
Ângela Sousa
AAAna M. Almeida
Ana M. Almeida
RFRúben Faria
Rúben Faria
KKKaridia Konate
Karidia Konate
Prisca BoisguérinPrisca Boisguérin
Prisca Boisguérin
Diana Barata CostaDiana Barata Costa
Diana Barata Costa

8 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RFRúben Faria
Rúben Faria
Prisca BoisguérinPrisca Boisguérin
Prisca Boisguérin
Ângela SousaÂngela Sousa
Ângela Sousa
Diana Barata CostaDiana Barata Costa
Diana Barata Costa
Mitochondria are membrane-bound cellular organelles of high relevance responsible for the chemical energy production used in most of the biochemical reactions of cells. Mitochondria have their own genome, the mitochondrial DNA (mtDNA). Inherited solely from the mother, this genome is quite susceptible to mutations, mainly due to the absence of an effective repair system. Mutations in mtDNA are associated with endocrine, metabolic, neurodegenerative diseases, and even cancer. Currently, therapeutic approaches are based on the administration of a set of drugs to alleviate the symptoms of patients suffering from mitochondrial pathologies. Mitochondrial gene therapy emerges as a promising strategy as it deeply focuses on the cause of mitochondrial disorder. The development of suitable mtDNA-based delivery systems to target and transfect mammalian mitochondria represents an exciting field of research, leading to progress in the challenging task of restoring mitochondria’s normal function. This review gathers relevant knowledge on the composition, targeting performance, or release profile of such nanosystems, offering researchers valuable conceptual approaches to follow in their quest for the most suitable vectors to turn mitochondrial gene therapy clinically feasible. Future studies should consider the optimization of mitochondrial genes’ encapsulation, targeting ability, and transfection to mitochondria. Expectedly, this effort will bring bright results, contributing to important hallmarks in mitochondrial gene therapy.

1 October 2019 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
RFRúben Faria
Rúben Faria
Ângela SousaÂngela Sousa
Ângela Sousa
ANAna R. Neves
Ana R. Neves
JQJoão A. Queiroz
João A. Queiroz
Diana Barata CostaDiana Barata Costa
Diana Barata Costa

1 October 2020 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
RFRúben Faria
Rúben Faria
TATânia Albuquerque
Tânia Albuquerque
ANAna R. Neves
Ana R. Neves
HBHimanshu Bhatt
Himanshu Bhatt
SBSwati Biswas
Swati Biswas
Diana Barata CostaDiana Barata Costa
Diana Barata Costa

18 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ANAna Raquel Neves
Ana Raquel Neves
TATânia Cristina de Oliveira Albuquerque
Tânia Cristina de Oliveira Albuquerque
RFRúben Faria
Rúben Faria
AGAna M. Gonçalves
Ana M. Gonçalves
Cecília R. SantosCecília R. Santos
Cecília R. Santos
Diana Barata CostaDiana Barata Costa
Diana Barata Costa
Despite the great progress over the past few decades in both the diagnosis and treatment of a great variety of human cancers, glioblastoma remains the most lethal brain tumor. In recent years, cancer gene therapy focused on non-viral vectors which emerged as a promising approach to glioblastoma treatment. Transferrin (Tf) easily penetrates brain cells of the blood–brain barrier, and its receptor is highly expressed in this barrier and glioblastoma cells. Therefore, the development of delivery systems containing Tf appears as a reliable strategy to improve their brain cells targeting ability and cellular uptake. In this work, a cell-penetrating peptide (WRAP5), bearing a Tf-targeting sequence, has been exploited to condense tumor suppressor p53-encoding plasmid DNA (pDNA) for the development of nanocomplexes. To increase the functionality of developed nanocomplexes, the drug Temozolomide (TMZ) was also incorporated into the formulations. The physicochemical properties of peptide/pDNA complexes were revealed to be dependent on the nitrogen to phosphate groups ratio and can be optimized to promote efficient cellular internalization. A confocal microscopy study showed the capacity of developed complexes for efficient glioblastoma cell transfection and consequent pDNA delivery into the nucleus, where efficient gene expression took place, followed by p53 protein production. Of promise, these peptide/pDNA complexes induced a significant decrease in the viability of glioblastoma cells. The set of data reported significantly support further in vitro research to evaluate the therapeutic potential of developed complexes against glioblastoma.